Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated -- Ignore unavailable to you. Want to Upgrade?

To: MFG ENG who wrote (49573)	1/22/2019 11:41:04 AM
From: stockdoc77	12 Recommendations Recommended By bobbseytwins2001 dorightbythem erickerickson erippetoe kdd999 and 7 more members Read Replies (1) \| Respond to of 63319

One of the rules of engagement here is to not speculate about the motives of any poster. I try not to do that. Your posts should be judged on their merits alone, even if it sends a distressing message. I'm not one to think that message board posting by shorts is much of an effective strategy. Most here have owned the stock for years and still have large profits. I doubt that any post on this board would result in significant selling. The shorts did their damage, now IMMU needs to get right with the FDA. In some sense, 132 has derisked significantly as the drug itself passed muster with FDA for approval. CMC is a process issue that can be fixed and should be this year. How severe the problems actually are will have to wait for the company meeting with FDA. Your posts suggest that a Class 2 refiling will be needed, and hence another 6 months till decision. I still hold hope that we can make this Class 1, but I have no basis for that.